Incyte Corporation vs Uber Technologies Inc — how do they compare? Incyte Corporation trades at $112.75 (market cap $22.99B), while Uber Technologies Inc trades at $70.36 (market cap $139.81B). The key difference: Uber Technologies Inc is far larger — about 6.1× Incyte Corporation's market cap, and Incyte Corporation is trading nearer its 52-week high, Uber Technologies Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Uber Technologies Inc for 88 Days on average.
| INCY | UBER | |
|---|---|---|
Market Cap | $22.99B | $139.81B |
Volume | 1,274,487 | 11,879,194 |
Sector | Health | Technology |
52-Week High | $129.93 | $99.72 |
52-Week Low | $83.80 | $65.94 |
Typical Hold Time | 33 Days | 88 Days |
Enterprise Value | $18.50B | $149.15B |
Signals from Pluang's Aura AI — not financial advice
INCY trades at $112.75, up 0.02% on the day, with a bullish technical signal from oscillators but bearish moving averages. The company reported strong Q2 2026 earnings, beating expectations with EPS of $3.09 versus $2.15, and revenue growth from $5.14B in 2025 to a projected $5.8B in 2026. Recent FDA approval for Atebrioz and a strategic push for post-JAKAFI growth highlight pipeline progress. Valuation ratios appear reasonable with a P/E of 14.45 and EV/EBITDA of 8.94.
Outlook is positive with a consensus price target of $132.07, implying 17% upside, supported by 52% analyst buy ratings. Risks include reliance on JAKAFI, which loses exclusivity after 2029, and near-term earnings volatility as seen in the Q4 2025 miss. Strong cash flow and profitability metrics suggest resilience, but execution on pipeline diversification is critical for sustained growth.
Uber (UBER) trades at $70.24, up 1.68% on the day, with a bearish technical signal from moving averages but strong fundamentals including 2025 revenue of $52.02 billion and net income of $10.05 billion. The company has beaten EPS estimates in two of the last three quarters and expanded its Uber Eats partnership with Costco to 47 states as of September 16, 2026. Operating cash flow grew to $10.10 billion in 2025, supporting a robust balance sheet with $6.98 billion in cash.
The outlook is positive given analyst consensus of a $104.72 price target and 82.54% buy ratings, though risks include a projected negative net cash flow in 2026 and competitive pressures from autonomous vehicle entrants. Upside is driven by earnings momentum and strategic expansions, while investor caution is warranted on execution and capital expenditure trends.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food delivery service providers, and shippers with carriers. The firm's on-demand technology platform could eventually be used for additional products and services, such as autonomous vehicles, delivery via drones, and Uber Elevate, which, as the firm refers to it, provides aerial ride-sharing. Uber Technologies is headquartered in San Francisco and operates in over 63 countries with over 110 million users that order rides or foods at least once a month. Approximately 76% of its gross revenue comes from ride-sharing and 22% from food delivery.
Read more on UBER →